Japan’s Takeda Pharmaceutical Co. is selling 18 products to Brazil’s Hypera Pharma for $825 million. The deal will include Neosaldina, a painkiller, as well as Nesina, a Type 2 diabetes treatment.
Once the deal is complete, Hypera said it will become the top pharma company in Brazil.
The deal is in line with Hypera’s focus on expanding its distribution reach in Latin America.
Takeda, meanwhile, has been focused on bringing down its debt load through $10 billion in divestitures. In addition to the deal with Hypera, Takeda recently sold its former U.S. headquarters to Horizon Therapeutics for $115 million.
Read the Reuters report.
